Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H38N4O6S2 |
| Molecular Weight | 542.712 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C\C=C1/NC(=O)[C@@H](CS)NC(=O)[C@H](NC(=O)C[C@H](OC(=O)[C@@H](NC1=O)C(C)C)\C=C\CCS)C(C)C
InChI
InChIKey=MEJLVLMAJJRLCR-GCCNXGTGSA-N
InChI=1S/C24H38N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15(9-7-8-10-35)11-18(29)27-19(13(2)3)23(32)26-17(12-36)22(31)25-16/h6-7,9,13-15,17,19-20,35-36H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1
| Molecular Formula | C24H38N4O6S2 |
| Molecular Weight | 542.712 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
377 ng/mL |
14 mg/m² 3 times / 4 weeks multiple, intravenous dose: 14 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
FR-135313 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1549 ng × h/mL |
14 mg/m² 3 times / 4 weeks multiple, intravenous dose: 14 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
FR-135313 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3 h |
14 mg/m² 3 times / 4 weeks multiple, intravenous dose: 14 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
FR-135313 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6% |
14 mg/m² 3 times / 4 weeks multiple, intravenous dose: 14 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
FR-135313 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 21:06:04 GMT 2025
by
admin
on
Tue Apr 01 21:06:04 GMT 2025
|
| Record UNII |
4MQ5UQAIB8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
390745-19-4
Created by
admin on Tue Apr 01 21:06:05 GMT 2025 , Edited by admin on Tue Apr 01 21:06:05 GMT 2025
|
PRIMARY | |||
|
9828788
Created by
admin on Tue Apr 01 21:06:05 GMT 2025 , Edited by admin on Tue Apr 01 21:06:05 GMT 2025
|
PRIMARY | |||
|
4MQ5UQAIB8
Created by
admin on Tue Apr 01 21:06:05 GMT 2025 , Edited by admin on Tue Apr 01 21:06:05 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
TARGET -> INHIBITOR |
COMPETITIVE INHIBITOR
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
